Welcome to our dedicated page for Ekso Bionics news (Ticker: EKSO), a resource for investors and traders seeking the latest updates and insights on Ekso Bionics stock.
Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) is a developer of exoskeleton and rehabilitation technologies for medical and industrial applications, and its news flow reflects this focus. Company press releases highlight product and technology developments, capital markets activity, strategic partnerships, and financial performance. Ekso Bionics regularly describes itself as an industry leader in exoskeleton technology that supports or enhances human strength, endurance, and mobility, with an emphasis on improving health and quality of life.
News updates for EKSO often cover clinical and rehabilitation initiatives, such as the launch of eksoUniversity, a virtual platform offering continuing education courses for physical therapists and physical therapy assistants who work with patients with neurological conditions. Other announcements detail agreements like Ekso Bionics’ role as the exclusive authorized U.S. sales agent and distributor for MediTouch’s BalanceTutor rehabilitation system, which uses a patented 4D perturbation treadmill and multiple sensors to help patients with impaired balance respond to unexpected disturbances while walking.
Investors and observers can also find coverage of Ekso Bionics’ technology roadmap, including its acceptance into the NVIDIA Connect program and related efforts to build a proprietary foundation model for human motion and integrate AI-enabled capabilities into its Enterprise Health and Personal Health exoskeleton devices. The company has reported proof-of-concept for an AI voice agent, Ekso Voice Agent, designed for intelligent control of its legacy EksoNR device.
In addition, EKSO news includes quarterly financial results, reverse stock split announcements, registered direct offerings of common stock, and secured loan agreements. Together, these updates provide insight into the company’s operating trends, capital structure decisions, and strategic priorities. This news page aggregates such disclosures so readers can follow developments in Ekso Bionics’ exoskeleton, rehabilitation, and AI initiatives over time.
Ekso Bionics Holdings reported a Q4 2020 revenue of $2.3 million, down from $3.7 million in Q4 2019, with gross margins improving to approximately 60%. The company saw a net loss of $4 million ($0.48 per share) for the quarter, compared to $2.7 million in 2019. Full-year revenue was $8.9 million, a decrease from $13.9 million in 2019, largely attributed to COVID-19 impacts. Despite a 45% reduction in cash used for operations, the company raised $40 million from a public offering in February 2021 to bolster its growth strategy.
Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) announced financial results for Q4 and full year 2020 will be released on February 25, 2021. A conference call is scheduled for 1:30 p.m. PT / 4:30 p.m. ET to discuss these results and recent business developments. Investors can participate by calling 877-407-3036 (domestic) or 201-378-4919 (international). A live webcast will be available in the "Investors" section of the company's website, with a replay accessible for two weeks afterward.
Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) announced the completion of its public offering, closing 3,902,440 shares of common stock at $10.25 each. The offering generated approximately $40 million in gross proceeds, with a 30-day option for underwriters to purchase an additional 585,366 shares. The proceeds will be allocated towards working capital, debt repayment, acquisitions, and other corporate purposes. This offering was managed by H.C. Wainwright & Co. The shares were issued under a previously filed registration statement with the SEC.
Ekso Bionics has announced an increase in its public offering to 3,902,440 shares at $10.25 each, aiming to raise approximately $40 million before expenses. The offering, managed by H.C. Wainwright & Co., is set to close around February 11, 2021. Additionally, an option for the underwriter to purchase 585,366 more shares is included. The funds will be used for working capital, debt repayment, and other corporate purposes, indicating the company's intention for growth and strengthening its financial position.
Ekso Bionics has announced a firm commitment underwriting agreement with H.C. Wainwright & Co. to purchase 975,610 shares of common stock at $10.25 each, aiming to raise approximately $10 million. This offering is expected to close on February 11, 2021. Additionally, the underwriter has a 30-day option to buy another 146,341 shares. The proceeds will be used for working capital, debt repayment, and potential acquisitions. The offering is registered under Form S-3 with the SEC.
Ekso Bionics (Nasdaq: EKSO) announced preliminary financial results for Q4 and FY 2020, with Q4 revenue estimated at $2.3 million, down from $3.7 million in Q4 2019. Total revenue for FY 2020 is about $8.9 million, compared to $13.9 million in 2019. Cash reserves rose to $12.9 million from $10.9 million year-over-year. CEO Jack Peurach highlighted strong performance despite COVID-19 challenges and a new subscription model aimed to expand their market. The company plans to report complete results in late February 2021.
Ekso Bionics (Nasdaq: EKSO) announced its participation in the H.C. Wainwright BioConnect 2021 Virtual Conference from January 11-14, 2021. Jack Peurach, CEO, and Jack Glenn, CFO, will present at this event. An on-demand company presentation will be available starting January 11 at 6:00 AM ET on the company's website. Ekso Bionics specializes in exoskeleton technology aimed at enhancing strength and mobility for medical and industrial applications, furthering its mission to amplify human potential.
Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) announced the election of Mary Ann Cloyd and Rhonda A. Wallen to its Board of Directors, effective December 29, 2020. Both directors bring extensive experience in business and healthcare. Cloyd has nearly 40 years of experience in public accounting and corporate governance, while Wallen has 25 years in life sciences and healthcare. Their insights are expected to enhance corporate strategy and value for stockholders as Ekso Bionics continues advancing its exoskeleton technology for medical and industrial applications.
Ekso Bionics Holdings (Nasdaq: EKSO) has announced a subscription-based order for its EVO exoskeleton from Cloverdale Foods Company, a family-owned meat company. This adoption highlights the effectiveness of EVO in reducing worker fatigue and enhancing productivity in the food processing sector. Cloverdale plans to implement the EVO Exoskeleton Program to ensure employee safety while meeting increased product demand. The EVO exoskeleton features a customized fit, reduced weight, and is rigorously tested for quality, aiming to enhance workplace efficiency and employee health.
Ekso Bionics (Nasdaq: EKSO) announced its Q3 financial results for 2020, reporting revenues of $2.9 million, a sequential increase from $2.3 million in Q2. Gross margins improved to 63% versus 53% a year earlier, attributed to higher selling prices and reduced production costs. Cash reserves stood at $14.5 million, bolstered by $2.5 million from warrant exercises. However, overall revenue decreased compared to last year due to COVID-19 impacts on sales. Despite challenges, the company launched the EVO exoskeleton, which received positive initial interest.
FAQ
What is the current stock price of Ekso Bionics (EKSO)?
What is the market cap of Ekso Bionics (EKSO)?
